Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Jul 29, 2008

Curis : Hsp90 Inhibitor CUDC-305 as Development Candidate from Targeted Cancer Drug Development Platform

Jul 21, 2008 - Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of targeted small molecule drug candidates for cancer treatment, announced that the Company has selected an orally available, synthetic small molecule inhibitor of heat shock protein 90 (Hsp90) as a development candidate from its targeted cancer drug development platform. In addition to demonstrating potent efficacy across a broad range of cancers in preclinical cancer models, CUDC-305 exhibits promising pharmacological features, particularly its high oral bioavailability, high tumor penetration and extended tumor retention...
...
In both laboratory and animal testing, CUDC-305 demonstrated high potency in vitro and/or in vivo across a wide range of cancers. Most notably, Curis scientists observed complete tumor regression following oral administration of CUDC-305 in a mouse xenograft model of acute myelogenous leukemia (AML). Tumor regression has also been observed after treatment of CUDC-305 in mouse xenograft models of breast, non-small cell lung, gastric cancer and glioblastoma brain cancers... Curis' Press Release -